Physician profile
Katherine Hammond
NPI 1962646216
$2,917.93
in general payments reported to CMS, 2019-2025
18 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.52 · 2020: $711 · 2021: $409 · 2022: $252 · 2023: $638 · 2024: $452 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $924.11 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Aquestive Therapeutics, INC. | $825.00 | 2020-2021 | |
| Neurelis, INC. | $241.13 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $173.93 | 2023-2025 | Xcopri |
| Greenwich Biosciences, INC. | $155.18 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $134.71 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $127.29 | 2023-2025 | Fycompa |
| Sumitomo Pharma America, INC. | $65.24 | 2023 | Aptiom |
| Eisai INC. | $51.93 | 2022-2023 | |
| Livanova USA, INC. | $36.94 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $30.02 | 2023 | |
| Pyros Pharmaceuticals, INC. | $29.62 | 2024 | Vigpoder |
| Zogenix INC. | $27.20 | 2021 | |
| Immedica Pharma US, INC. | $22.31 | 2023 | |
| Acadia Pharmaceuticals INC | $21.04 | 2023 | Daybue |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.51 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $16.63 | 2024 | Qelbree |
| Azurity Pharmaceuticals, INC. | $15.14 | 2025 | Zonisade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.